The international staging system (ISS) is the most commonly used risk-stratification system for patients with multiple myeloma (MM) and is determined by serum albumin and β2-microglobulin levels. In the two determinants, β2-microglobulin levels are frequently observed to be elevated in patients with myeloma, particularly in those with renal impairment. In comparison with patients with intact immunoglobulin myeloma, patients with LC myeloma do not necessarily show decreased levels of serum albumin. The clinical impact of ISS in patients with LCMM, in particular the distinction between ISS I and II, may be complicated due to non-decreased levels of serum albumin in both stages. Accordingly, we have attempted to assess clinical relevance of the ISS in patients with LC myeloma. The clinical data of 1899 patients with MM diagnosed between January 2001 and December 2012 were collected from 38 affiliated hospitals of the Japanese Society of Myeloma. Significant difference was not found between stage I (n = 72) and stage II (n = 92) in LC myeloma patients (n = 307). The mean serum albumin concentration of patients with LC myeloma was within the reference range but higher than that of patients with IgG + IgA myeloma (n = 1501), which complicates the distinction between ISS stage I and II myeloma. Patients with LC myeloma had low frequencies of t(4; 14) and high frequency of elevated lactate dehydrogenase, and despite a relevant amount of missing data in our registry (R-ISS stage I; n = 11, stage II; n = 32, and stage III: n = 18), the information included in the R-ISS scoring system seems to be more accurate than ISS to obtain a reliable risk stratification approach in non-ISS stage III LC myeloma patients.

CONFLICT OF INTERESTS

None declared.

REFERENCES

1Drayson M, Begum G, Basu S, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood. 2006; 108(6): 2013-2019.
10.1182/blood-2006-03-008953
CAS PubMed Web of Science® Google Scholar
2Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015; 33(26): 2863-2869.
10.1200/JCO.2015.61.2267
CAS PubMed Web of Science® Google Scholar
3Ozaki S, Handa H, Saitoh T, et al. Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J. 2015; 5(9): e349.
10.1038/bcj.2015.79
CAS PubMed Web of Science® Google Scholar
4Zhang JJ, Sun WJ, Huang ZX, et al. Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study. World J Surg Oncol. 2014; 12(1): 234.
10.1186/1477-7819-12-234
PubMed Web of Science® Google Scholar
5Sasaki K, Shah N, Bashir Q, et al. Outcome of patients with light chain multiple myeloma compared to IgG/IgA myeloma after autologous stem cell transplant. Blood. 2015; 126(23): 3194.
Google Scholar
6Jagannath S, Barlogie B, Berenson JR, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer. 2005; 103(6): 1195-1200.
10.1002/cncr.20888
CAS PubMed Web of Science® Google Scholar
7Chen JH, Hsu SN, Huang TC, et al. Prognostic significance of initial serum albumin and 24 hour daily protein excretion before treatment in multiple myeloma. PLoS One. 2015; 10(6):e0128905. https://doi.org/10.1371/journal.pone.0128905
10.1371/journal.pone.0128905
PubMed Web of Science® Google Scholar
8Kim JE, Yoo C, Lee DH, Kim SW, Lee JS, Suh C. Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma. Ann Hematol. 2010; 89(4): 391-397. https://doi.org/10.1007/s00277-009-0841-4
10.1007/s00277-009-0841-4
CAS PubMed Web of Science® Google Scholar
9Majithia N, Rajkumar SV, Lacy MQ, et al. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents. Leukemia. 2016; 30(11): 2208-2213. https://doi.org/10.1038/leu.2016.147
10.1038/leu.2016.147
CAS PubMed Web of Science® Google Scholar
10Dich J, Hansen SE, Thieden HI. Effect of albumin concentration and colloid osmotic pressure on albumin synthesis in the perfused rat liver. Acta Physiol Scand. 1973; 89(3): 352-358.
10.1111/j.1748-1716.1973.tb05530.x
CAS PubMed Web of Science® Google Scholar
11Tracht ME, Tallal L, Tracht DG. Intrinsic hepatic control of psma albumin concentration. Life Sci. 1967; 6(24): 2621-2628.
10.1016/0024-3205(67)90112-9
CAS PubMed Google Scholar
12Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005; 106(8): 2837-2840.
10.1182/blood-2005-04-1411
CAS PubMed Web of Science® Google Scholar
13Cavo M, Terragna C, Renzulli M, et al. Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. J Clin Oncol. 2006; 24(3): e4-e5. https://doi.org/10.1200/JCO.2005.04.7506
10.1200/JCO.2005.04.7506
PubMed Google Scholar
14Moreau P, Facon T, Leleu X, et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood. 2002; 100(5): 1579-1583.
10.1182/blood-2002-03-0749
CAS PubMed Web of Science® Google Scholar
15Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003; 101(11): 4569-4575.
10.1182/blood-2002-10-3017
CAS PubMed Web of Science® Google Scholar
16Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002; 99(6): 2185-2191.
10.1182/blood.V99.6.2185
CAS PubMed Web of Science® Google Scholar
17Chang H, Sloan S, Li D, et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol. 2004; 125(1): 64-68.
10.1111/j.1365-2141.2004.04867.x
PubMed Web of Science® Google Scholar

Citing Literature

Volume36, Issue5

December 2018

Pages 792-800

Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma

Abstract

CONFLICT OF INTERESTS

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma

Abstract

CONFLICT OF INTERESTS

REFERENCES

Citing Literature

References

Related

Information